CNV		Amplification	1q21	Multiple Myeloma		Thalidomide	Targeted Drug	0	0	Level B	Amplification of 1p21 increases the risk of multiple myeloma progression. 		National Comprehensive Cancer Network. Multiple Myeloma NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf. Accessed November 5, 2016.	Guideline
CNV		Deletion	5q	Myelodysplastic Syndromes		Lenalidomide	Targeted Drug	1		FDA-Approved	del(5q) concurrent with symptomatic anemia is associated with sensitivity to lenalidomide. Patients with del(5q) may have a higher risk of concomittant TP53 mutations.		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	Guideline
Rearrangement	PDGFRB	Translocation	5q31-33	Myelodysplastic Syndromes		Imatinib	Targeted Drug	1		FDA-Approved	PDGFRB translocations are associated with sensitivity to imatinib in Chronic Myelomonocytic Leuekmia.		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	Guideline
Mutation	MAP2K1	SNV	C121S	Melanoma	Metastatic	Selumetinib	Targeted Drug	0		Level D			Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29(22):3085-96.	Journal
Mutation	MAP2K1	SNV	C121S	Melanoma	Metastatic	Vemurafenib	Targeted Drug	0		Level D			Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29(22):3085-96.	Journal
Mutation	PIK3CA	SNV	C420R	Breast Cancer	Metastatic	Pictilisib	Targeted Drug	1		Level D	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.		O'brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	Journal
Mutation	KIT	InDel	C620del	GIST	Metastatic	Imatinib	Targeted Drug	1					Demetri GD, Von mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347(7):472-80.	Journal
Mutation	NOTCH1	SNV	D1517N	Head and Neck Squamous Cell Carcinoma	Metastatic	MK-0752	Targeted Drug	0		Level D			Unknown	Unknown
Mutation	KIT	SNV	D52N	Myeloproliferative Disorders		Imatinib	Targeted Drug	1		Level B			Kimura A, Nakata Y, Katoh O, Hyodo H. c-kit Point mutation in patients with myeloproliferative disorders. Leuk Lymphoma. 1997;25(3-4):281-7.	Journal
Mutation	KIT	SNV	D52N	Myeloproliferative Disorders		Sunitinib	Targeted Drug	1		Level B			Kimura A, Nakata Y, Katoh O, Hyodo H. c-kit Point mutation in patients with myeloproliferative disorders. Leuk Lymphoma. 1997;25(3-4):281-7.	Journal
Mutation	MAP2K1	SNV	D67N	Lung Cancer	Metastatic	Erlotinib	Targeted Drug	0		Level D			Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	Journal
CNV	RB1	Deletion	del(13)	Multiple Myeloma					0	Level B	Deletion of chromosome 13 seems to have an amplifying effect on cell cycle gene expression and is reported to be associated with short event-free survival (EFS) and overall survival (OS). This copy loss event results in haploinsufficiency of RB1 and other genes mapped to chromosome 13. 		National Comprehensive Cancer Network. Multiple Myeloma NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf. Accessed November 5, 2016.	Guideline
CNV	TP53	Deletion	del(17p13)	Multiple Myeloma					0	Level B	Deletion of 17p13 leads to LoH of TP53 and is considered a high-risk feature of multiple myeloma.		National Comprehensive Cancer Network. Multiple Myeloma NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf. Accessed November 5, 2016.	Guideline
CNV		Deletion	del(1p10)|del(19q10)	Glioma		Alkylating Chemotherapy	Drug Class	1	1		Co-deletion of 1p and 19q is associated with oligodendroglial histology, and may indicate a favorable prognosis and sensitivity to alkylating chemotherapy.		National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	Guideline
Mutation	NOTCH1	SNV	E424K	Head and Neck Squamous Cell Carcinoma	Metastatic	MK-0752	Targeted Drug	0		Level D			Unknown	Unknown
Mutation	PIK3CA	SNV	E542K	Breast Cancer	Metastatic	Pictilisib	Targeted Drug	1		Level D	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.		O'brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	Journal
Mutation	PIK3CA	SNV	E542Q	Breast Cancer	Metastatic	Pictilisib	Targeted Drug	1		Level D	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.		O'brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	Journal
Mutation	PIK3CA	SNV	E545A	Breast Cancer	Metastatic	Pictilisib	Targeted Drug	1		Level D	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.		O'brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	Journal
Mutation	PIK3CA	SNV	E545D	Breast Cancer	Metastatic	Pictilisib	Targeted Drug	1		Level D	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.		O'brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	Journal
Mutation	PIK3CA	SNV	E545D	Breast Cancer	Metastatic	Pictilisib	Targeted Drug	1		Level D	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.		O'brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	Journal
Mutation	PIK3CA	SNV	E545G	Breast Cancer	Metastatic	Pictilisib	Targeted Drug	1		Level D	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.		O'brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	Journal
Mutation	PIK3CA	SNV	E545K	Breast Cancer	Metastatic	Pictilisib	Targeted Drug	1		Level D	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.		O'brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	Journal
Mutation	PIK3CA	SNV	E545Q	Breast Cancer	Metastatic	Pictilisib	Targeted Drug	1		Level D	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.		O'brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	Journal
Mutation	NOTCH1	SNV	E719	Head and Neck Squamous Cell Carcinoma	Metastatic	MK-0752	Targeted Drug	0		Level D			Unknown	Unknown
Mutation	SETBP1	Missense	E858|T864|I865|D868|S869|G870	Myelodysplastic Syndromes					0	Level B	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	Guideline
Mutation	NOTCH1	SNV	F1411F	Head and Neck Squamous Cell Carcinoma	Metastatic	MK-0752	Targeted Drug	0		Level D			Unknown	Unknown
Mutation	NOTCH1	InDel	F357del	Head and Neck Squamous Cell Carcinoma	Metastatic	MK-0752	Targeted Drug	1		Level D			Unknown	Unknown
Mutation	KIT	InDel	F504insAY	GIST	Metastatic	Imatinib	Targeted Drug	0			Requires increased dose of TKI		Prenen H, Guetens G, De boeck G, et al. Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines. Pharmacology. 2006;77(1):11-6.	Journal
Mutation	PIK3CA	SNV	G1049R	Breast Cancer	Metastatic	Pictilisib	Targeted Drug	1		Level D	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.		O'brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	Journal
Mutation	PIK3CA	SNV	G1049S	Breast Cancer	Metastatic	Pictilisib	Targeted Drug	1		Level D	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.		O'brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	Journal
Mutation	KRAS	SNV	G12	Colorectal Cancer	Metastatic	Cetuximab	Targeted Drug	1		Level B	exon 2 comment		National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	Guideline
Mutation	NRAS	Missense	G12|G13|Q61	Myelodysplastic Syndromes					0	Level B	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	Guideline
Mutation	NRAS	SNV	G12A	Melanoma	Metastatic	Selumetinib	Targeted Drug	1		Level B	Presence of this variant may suggest sensitivity to Selumetinib.		Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	Journal
Mutation	NRAS	SNV	G12C	Melanoma	Metastatic	Selumetinib	Targeted Drug	1		Level B	Presence of this variant may suggest sensitivity to Selumetinib.		Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	Journal
Mutation	NRAS	SNV	G12D	Melanoma	Metastatic	Selumetinib	Targeted Drug	1		Level B	Presence of this variant may suggest sensitivity to Selumetinib.		Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	Journal
Mutation	KRAS	SNV	G12D	Pancreatic Cancer					0	Level A	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	10.1038/ctg.2016.18	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	Journal
Mutation	NRAS	SNV	G12R	Melanoma	Metastatic	Selumetinib	Targeted Drug	1		Level B	Presence of this variant may suggest sensitivity to Selumetinib.		Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	Journal
Mutation	NRAS	SNV	G12S	Melanoma	Metastatic	Selumetinib	Targeted Drug	1		Level B	Presence of this variant may suggest sensitivity to Selumetinib.		Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	Journal
Mutation	NRAS	SNV	G12V	Melanoma	Metastatic	Selumetinib	Targeted Drug	1		Level B	Presence of this variant may suggest sensitivity to Selumetinib.		Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	Journal
Mutation	KRAS	SNV	G13	Colorectal Cancer	Metastatic	Panitumumab	Targeted Drug	1		Level B			National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	Guideline
Mutation	NRAS	SNV	G13A	Melanoma	Metastatic	Selumetinib	Targeted Drug	1		Level B	Presence of this variant may suggest sensitivity to Selumetinib.		Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	Journal
Mutation	NRAS	SNV	G13D	Melanoma	Metastatic	Selumetinib	Targeted Drug	1		Level B	Presence of this variant may suggest sensitivity to Selumetinib.		Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	Journal
Mutation	NRAS	SNV	G13R	Melanoma	Metastatic	Selumetinib	Targeted Drug	1		Level B	Presence of this variant may suggest sensitivity to Selumetinib.		Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	Journal
Mutation	NRAS	SNV	G13V	Melanoma	Metastatic	Selumetinib	Targeted Drug	1		Level B	Presence of this variant may suggest sensitivity to Selumetinib.		Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	Journal
Mutation	NOTCH1	SNV	G481S	Head and Neck Squamous Cell Carcinoma	Metastatic	MK-0752	Targeted Drug	0		Level D			Unknown	Unknown
Mutation	PIK3CA	SNV	H1047L	Breast Cancer	Metastatic	Pictilisib	Targeted Drug	1		Level D	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.		O'brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	Journal
Mutation	PIK3CA	SNV	H1047R	Breast Cancer	Metastatic	Pictilisib	Targeted Drug	1		Level D	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.		O'brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	Journal
Mutation	PIK3CA	SNV	H1047Y	Breast Cancer	Metastatic	Pictilisib	Targeted Drug	1		Level D	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.		O'brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	Journal
Mutation	PIK3CA	SNV	H701P	Breast Cancer	Metastatic	Pictilisib	Targeted Drug	1		Level D	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.		O'brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	Journal
Mutation	PTEN	Frameshift	K267*fs*9	Breast Cancer	Metastatic					Level D			Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010;28(6):1075-83.	Journal
Mutation	PTEN	Frameshift	K267*fs*9	Breast Cancer	Metastatic					Level D			Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010;28(6):1075-83.	Journal
Mutation	MAP2K1	SNV	K57N	Lung Cancer	Metastatic	Erlotinib	Targeted Drug	0		Level D			Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	Journal
Mutation	MAP2K1	SNV	K57N	Lung Cancer	Metastatic	Erlotinib	Targeted Drug	0		Level D			Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	Journal
Mutation	MAP2K1	SNV	K57N	Lung Cancer	Metastatic	Gefitinib	Targeted Drug	0		Level D			Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	Journal
Mutation	MAP2K1	SNV	K57N	Lung Cancer	Metastatic	Gefitinib	Targeted Drug	0		Level D			Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	Journal
Mutation	MAP2K1	SNV	K57N	Lung Cancer	Metastatic	Selumetinib	Targeted Drug	1		Level D			Unknown	Unknown
Mutation	PIK3CA	SNV	L633E	Breast Cancer	Metastatic	Pictilisib	Targeted Drug	1		Level D	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.		O'brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	Journal
Mutation	PIK3CA	SNV	L633V	Breast Cancer	Metastatic	Pictilisib	Targeted Drug	1		Level D	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.		O'brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	Journal
Mutation	EGFR	SNV	L858R	Lung Cancer		ASP8273	Targeted Drug	1		Level A	ASP8273 is being evaluated for clinical efficacy in patients with T790M or L858R mutations.	10.1186/s13045-016-0268-z	Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9:34.	Journal
Mutation	EGFR	SNV	L858R	Lung Cancer		Dacomitinib	Targeted Drug	1		Level A	Dacomitinib is being evaluated in comparison with gefitinib for the treatment of locally advanced or metastatic non-small cell lung cancer.	10.1016/j.tips.2016.09.003	Ke EE, Wu YL. EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?. Trends Pharmacol Sci. 2016;37(11):887-903.	Journal
Mutation	EGFR	SNV	L858R	Lung Cancer		EGF816	Targeted Drug	1		Level A	EGF816 demonstrated clinical activity in a Phase 1 trial of patients with L858R and T790M mutations.	10.1186/s13045-016-0268-z	Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9:34.	Journal
Mutation	EGFR	SNV	L858R	Lung Cancer		PF-06747775	Targeted Drug	1		Level A	PF-06747775, a small molecule inhibitor of EGFR T790M, is being evaluated in advanced NSCLC patients with EGFR mutations (del 19 and L858R with or without T790M).	10.1186/s13045-016-0268-z	Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9:34.	Journal
Mutation	PIK3CA	SNV	M1043I	Breast Cancer	Metastatic	Pictilisib	Targeted Drug	1		Level D	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.		O'brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	Journal
Mutation	PIK3CA	SNV	M1043I	Breast Cancer	Metastatic	Pictilisib	Targeted Drug	1		Level D	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.		O'brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	Journal
Mutation	PIK3CA	Frameshift	N1068fs*4	Breast Cancer	Metastatic	Pictilisib	Targeted Drug	1		Level D	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.		O'brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	Journal
Mutation	BCOR	Missense	N1425	Myelodysplastic Syndromes					0	Level B	More frequent in Chronic Myelomonocytic Leukemia.		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	Guideline
Mutation	MAP2K1	SNV	P124L	Melanoma	Metastatic	Selumetinib	Targeted Drug	0		Level B	Presence of this variant may suggest resistance to Selumetinib.		Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	Journal
Mutation	MAP2K1	SNV	P124L	Melanoma	Metastatic	Vemurafenib	Targeted Drug	0		Level D	Presence of this variant in vitro suggests resistance to PLX4720, a precursor to Vemurafenib, in metastatic melanoma. 		Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	Journal
Mutation	NOTCH1	SNV	P422S	Head and Neck Squamous Cell Carcinoma	Metastatic	MK-0752	Targeted Drug	0		Level D			Unknown	Unknown
Mutation	PIK3CA	SNV	P539R	Breast Cancer	Metastatic	Pictilisib	Targeted Drug	1		Level D	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.		O'brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	Journal
Mutation	SRSF2	Missense	P95	Myelodysplastic Syndromes					0	Level B	Most frequent in Chronic Myelomonocytic Leukemia.		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	Guideline
Mutation	NOTCH1	SNV	Q1214	Head and Neck Squamous Cell Carcinoma	Metastatic	MK-0752	Targeted Drug	0		Level D			Unknown	Unknown
Mutation	PIK3CA	SNV	Q546K	Breast Cancer	Metastatic	Pictilisib	Targeted Drug	1		Level D	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.		O'brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	Journal
Mutation	MAP2K1	SNV	Q56P	Lung Cancer	Metastatic	Gefitinib	Targeted Drug	0		Level D			Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	Journal
Mutation	MAP2K1	SNV	Q56P	Lung Cancer	Metastatic	Selumetinib	Targeted Drug	1		Level D	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).		Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	Journal
Mutation	MAP2K1	SNV	Q56P	Melanoma	Metastatic	Vemurafenib	Targeted Drug	0		Level D	Presence of this variant in vitro suggests resistance to PLX4720, a precursor to Vemurafenib, in metastatic melanoma. 		Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	Journal
Mutation	NRAS	SNV	Q61E	Melanoma	Metastatic	Selumetinib	Targeted Drug	1		Level B	Presence of this variant may suggest sensitivity to Selumetinib.		Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	Journal
Mutation	NRAS	SNV	Q61H	Melanoma	Metastatic	Selumetinib	Targeted Drug	1		Level B	Presence of this variant may suggest sensitivity to Selumetinib.		Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	Journal
Mutation	NRAS	SNV	Q61L	Melanoma	Metastatic	Selumetinib	Targeted Drug	1		Level B	Presence of this variant may suggest sensitivity to Selumetinib.		Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	Journal
Mutation	NRAS	SNV	Q61L	Melanoma	Metastatic	Selumetinib	Targeted Drug	1		Level B	Presence of this variant may suggest sensitivity to Selumetinib.		Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	Journal
Mutation	NRAS	SNV	Q61P	Melanoma	Metastatic	Selumetinib	Targeted Drug	1		Level B	Presence of this variant may suggest sensitivity to Selumetinib.		Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	Journal
Mutation	NRAS	SNV	Q61R	Melanoma	Metastatic	Selumetinib	Targeted Drug	1		Level B	Presence of this variant may suggest sensitivity to Selumetinib.		Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	Journal
Mutation	IDH2	Missense	R140Q|R172	Myelodysplastic Syndromes					0	Level B	More frequent in Acute Myeloid Leukemia.		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://wwber 5, 2016.	Guideline
Rearrangement	EWS-FLI1	Translocation	t(11;22)	Ewing's Sarcoma					1	Level B	EWS-FLI1 translocations may be associated with improved prognosis in Ewing's Sarcoma; however, current treatments result in patient outcomes indistinguishable by EWS-FLI1 status.		National Comprehensive Cancer Network. Bone Cancer (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf. Accessed November 6, 2016.	Guideline
Rearrangement	COL1A1-PDGFB	Fusion	t(17;22)(q22;q13)	Dermatofibrosarcoma		Imatinib	Targeted Drug	1		FDA-Approved	Imatinib has shown clinical activity against localized and metastatic DFSP tumors containing t(17;22)(q22;q13). 		National Comprehensive Cancer Network. Dermatofibrosarcoma NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/dfsp_blocks.pdf. Accessed November 5, 2016.	Guideline
Rearrangement	IGH	Translocation	t(4;14)(q16;q32)	Multiple Myeloma					0	Level B	A translocation between 4 and 14 [t(4;14)] has been reported in several studies to be associated with poor prognosis.		National Comprehensive Cancer Network. Multiple Myeloma NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf. Accessed November 5, 2016.	Guideline
Rearrangement	RUNX1-MTG8	Translocation	t(8;21)(q22;q22)	Myelodysplastic Syndromes		HDAC inhibitors+DNMT inhibitors	Targeted Drug	1		Level D	t(8;21)(q22;q22) results in the expression of fusion protein RUNX1-MTG8, which recruits histone deacetylases (HDAC) to silence RUNX1 target genes (such as IL-3). Combined use of HDAC inhibitors and DNMT inhibitors may rescue RUNX1 target genes.		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	Guideline
Mutation	MET	SNV	T1010I	Head and Neck Squamous Cell Carcinoma	Metastatic	SU11274	Targeted Drug	1		Level D	Presence of this variant may suggest sensitivity to SU11274.		Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	Journal
Mutation	EGFR	SNV	T790M	Lung Cancer		ASP8273	Targeted Drug	1		Level A	ASP8273 is being evaluated for clinical efficacy in patients with T790M or L858R mutations.	10.1186/s13045-016-0268-z	Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9:34.	Journal
Mutation	EGFR	SNV	T790M	Lung Cancer		Durvalumab+Osimertinib	Targeted Drug	1		Level A	Durvalumab (a PD-L1 inhibitor), is being evaluated in combination with Osimertinib (an EGFR-TKI) in patients with sensitizing EGFR mutations or T790M.	10.1016/S1556-0864(16)30246-5	Ahn MJ, Yang J, Yu H, et al. 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial. J Thorac Oncol. 2016;11(4 Suppl):S115.	Journal
Mutation	EGFR	SNV	T790M	Lung Cancer		EGF816	Targeted Drug	1		Level A	EGF816 demonstrated clinical activity in a Phase 1 trial of patients with L858R and T790M mutations.	10.1186/s13045-016-0268-z	Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9:34.	Journal
Mutation	EGFR	SNV	T790M	Lung Cancer		HM61713	Targeted Drug	1		Level A	HM61713 showed clinical activity in patients with an EGFR T790M mutation in a Phase I trial.	10.1016/S1556-0864(16)30243-X	K. Park, et al., BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M + NSCLC: Efficacy and safety at the RP2D, J Clin Oncol, 34 (2016), p. abstr9055	Journal
Mutation	EGFR	SNV	T790M	Lung Cancer		Osimertinib	Targeted Drug	1		Level A	Osimertinib is being evaluated in patients who have progressed following treatment with an EGFR TKI.	10.1016/j.tips.2016.09.003	Ke EE, Wu YL. EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?. Trme patients in a 130-patient trial.	10.1056/NEJMoa1413654	Sequist LV, Soria JC, Goldman JW, et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015;372(18):1700-9.	Journal
Mutation	EGFR	SNV	T790M	Lung Cancer		Tyrosine-Kinase Inhibitor	Drug Class	0			Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.		National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.	Guideline
Mutation	BRAF	SNV	V600	Melanoma		BRAF Inhibitors	Drug Class	1			Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.		National Comprehensive Cancer Network. Melanoma NCCN Evidence Blocks (Version 3.2016). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf	Guideline
Mutation	BRAF	SNV	V600	Melanoma		Dabrafenib+Trametinib	Targeted Drug	1		FDA-Approved	Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.		National Comprehensive Cancer Network. Melanoma NCCN Evidence Blocks (Version 3.2016). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf	Guideline
Mutation	BRAF	SNV	V600	Melanoma		Vemurafenib+Cobimetinib	Targeted Drug	1		FDA-Approved	Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.		National Comprehensive Cancer Network. Melanoma NCCN Evidence Blocks (Version 3.2016). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf	Guideline
Mutation	BRAF	SNV	V600E	Melanoma		Bevacizumab	Targeted Drug	1		Level D	Administration of bevacizumab in a dabrafenib-resistant cell line counteracted the tumor growth stimulating effect of administering dabrafenib post-resistance.	10.3892/ijo.2016.3594	Caporali S, Alvino E, Lacal PM, et al. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor. Int J Oncol. 2016;49(3):1164-74.	Journal
Mutation	BRAF	SNV	V600E	Melanoma		Bleomycin	Targeted Drug	1		Level D	Three human melanoma cell lines displayed sensitivity to bleomycin, particularly when co-administered with human interferon-beta gene or herpes simplex virus thymidine kinase/ganciclovir suicide gene lipofection.		Fondello C, Agnetti L, Villaverde MS, Simian M, Glikin GC, Finocchiaro LM. The combination of bleomycin with suicide or interferon-B gene transfer is able to efficiently eliminate human melanoma tumor initiating cells. Biomed Pharmacother. 2016;83:290-301.	Journal
Mutation	BRAF	SNV	V600E	Melanoma		Bleomycin+Electrochemotherapy+Vemurafenib	Targeted Drug	1		Level D	The combination of bleomycin, electrochemotherapy (ECT), and vemurafenib was found to be effective in two human melanoma cell lines.	10.1515/raon-2016-0042	Dolinsek T, Prosen L, Cemazar M, Potocnik T, Sersa G. Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors. Radiol Oncol. 2016;50(3):274-9.	Journal
Mutation	BRAF	SNV	V600E	Colorectal Neuroendocrine Tumors	Metastatic	BRAF Inhibitors+MEK Inhibitors	Drug Class	1		Level D	Two patients with metastatic colorectal neuroendocrine tumors refractory to treatment exhibited a durable response to combined BRAF-MEK inhibition.	10.1158/2159-8290.CD-15-1192	Klempner SJ, Gershenhorn B, Tran P, et al. BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy. Cancer Discov. 2016;6(6):594-600.	Journal
Mutation	BRAF	SNV	V600E	Colorectal Cancer	Metastatic	Cetuximab	Targeted Drug	0	0	Level B	BRAF V600E alterations predict resistance to treatment with Cetuximab, both alone antesting response to dabrafenib in pediatric glioma patients is underway.		GlaxoSmithKline. A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2016 Nov 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT01677741 NLM Identifier: NCT01677741.	Clinical Trial
Mutation	BRAF	SNV	V600E	Melanoma		GSK2126458A	Targeted Drug	1		Level D	Administration of GSK2126458A, a PI3K/AKT/mTOR pathway inhibitor, in a dabrafenib-resistant cell line counteracted the tumor growth stimulating effect of administering dabrafenib post-resistance.	10.3892/ijo.2016.3594	Caporali S, Alvino E, Lacal PM, et al. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor. Int J Oncol. 2016;49(3):1164-74.	Journal
Mutation	BRAF	SNV	V600E	Melanoma		Ipilimumab+Vemurafenib	Targeted Drug	1		Level A	The combination of ipilimumab and vemurafenib in a sequencing strategy showed limited efficacy in a phase II study.	10.1186/s40425-016-0148-7	Amin A, Lawson DH, Salama AK, et al. Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma. J Immunother Cancer. 2016;4:44.|Bristol-Myers Squibb. Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2016 Nov 7]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01673854 NLM Identifier: NCT01673854.	Journal|Clinical Trial
Mutation	BRAF	SNV	V600E	Melanoma		Ixazomib+Interferon-alpha	Targeted Drug	1		Level D	Preclinical evidence suggests the combination of proteasome inhibitor ixazomib with interferon-alpha may negatively impact tumor cell viability in melanoma, particularly in patients with BRAF V600E mutations.	10.18632/oncotarget.12791	Suarez-kelly LP, Kemper GM, Duggan MC, et al. The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma. Oncotarget. 2016;	Journal
Mutation	BRAF	SNV	V600E	Melanoma		Mito-CP	Targeted Drug	1		Level D	Mitochondria-targeted metabolism-interferring agent mito-CP (mitochondria-targeted carboxy-proxyl) demonstrated a tumor-suppressing effect in BRAF V600E-mutated melanoma mouse models, including models that had developed resistance to vemurafenib.	10.1080/15384047.2016.1250987	Hong SK, Starenki D, Wu PK, Park JI. Suppression of B-Raf(V600E) melanoma cell survival by targeting mitochondria using triphenyl-phosphonium-conjugated nitroxide or ubiquinone. Cancer Biol Ther. 2016;	Journal
Mutation	BRAF	SNV	V600E	Colorectal Cancer	Metastatic	Panitumumab	Targeted Drug	0	0	Level B	BRAF V600E alterations predict resistance to treatment with Panitumumab, both alone and in combination with alkylatixenograft (PDOX) model suggests some vemurafenib-resistant BRAF-V600E-mutated melanomas may be sensitive to trametinib (but not cobimetinib) treatment.	10.18632/oncotarget.12328	Kawaguchi K, Murakami T, Chmielowski B, et al. Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model. Oncotarget. 2016;	Journal
Mutation	BRAF	SNV	V600E	Glioma		Vemurafenib	Targeted Drug	1		Level A	BRAF V600E mutations in pediatric glioma patients may sensitize a response to BRAF inhibitors. A clinical trial testing response to vemurafenib in pediatric glioma patients is underway.		Nicolaides, T; Genentech, Inc. Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2016 Nov 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT01748149 NLM Identifier: NCT01748149.	Clinical Trial
Mutation	BRAF	SNV	V600E	Glioma		Vemurafenib+EGFR Inhibitor	Targeted Drug	1		Level D	Vemurafenib monotherapy is efficacious in preclinical models of pediatric gliomas harboring BRAF V600E mutations, but resistance quickly develops. EGFR inhibition appears to rescue the effects of vemurafenib in these models.	10.18632/oncotarget.4014	Yao TW, Zhang J, Prados M, Weiss WA, James CD, Nicolaides T. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy. Oncotarget. 2015;6(26):21993-2005.	Journal
Mutation	MPL	SNV	W515L	Myeloproliferative Disorders	Metastatic	EXEL-8232	Targeted Drug	1		Level D	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo. 		Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	Journal
Mutation	PIK3CA	SNV	Y1021C	Breast Cancer	Metastatic	Pictilisib	Targeted Drug	1		Level D	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.		O'brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	Journal
MSI		MSI-High		Colorectal Cancer		5-Fluorouracil	Targeted Drug	0	1	Level B	Patients with MSI-High colorectal cancer often have a favorable prognosis. These patients do not benefit from, and may be resistant to, 5-fluorouracil therapy.		National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	Guideline
Germline Mutation	MLH1	SNV		Colorectal Cancer		5-Fluorouracil	Targeted Drug		1	Level B	Patients with defects in DNA mismatch repair genes often have a favorable prognosis and a decreased likelihood of metastasis. These patients do not benefit from, and may be resistant to, 5-fluorouracil therapy.		National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	Guideline
Germline Mutation	MSH2	SNV		Colorectal Cancer		5-Fluorouracil	Targeted Drug		1	Level B	Patients with defects in DNA mismatch repair genes often have a favorable prognosis and a decreased likelihood of metastasis. These patients do not benefit from, and may be resistant to, 5-fluorouracil therapy.		National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	Guideline
Germline Mutation	MSH6	SNV		Colorectal Cancer		5-Fluorouracil	Targeted Drug		1	Level B	Patients with defects in DNA mismatch repair genes often have a favorable prognosis and a decreased likelihood of metastasis. These patients do not benefit from, and may be recreased likelihood of metastasis. These patients do not benefit from, and may be resistant to, 5-fluorouracil therapy.		National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	Guideline
Germline Mutation	EPCAM	SNV		Colorectal Cancer		5-Fluorouracil	Targeted Drug		1	Level B	Patients with defects in DNA mismatch repair genes often have a favorable prognosis and a decreased likelihood of metastasis. These patients do not benefit from, and may be resistant to, 5-fluorouracil therapy.		National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	Guideline
CNV	AR	Amplification		Prostate Cancer	Castration Resistant Prostate Cancer	Abiraterone	Targeted Drug	1		FDA-Approved	Androgen receptor activation may predict sensitivity to second generation androgen deprivation or direct androgen inhibitors.		National Comprehensive Cancer Network. Prostate Cancer NCCN Evidence Blocks (Version 3.2016). https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf. Accessed November 5, 2016.	Guideline
Mutation	EGFR	SNV		Lung Cancer	Metastatic	Afatinib	Targeted Drug	1		FDA-Approved	Mutant EGFR may suggest sensitivity to Afatinib as a first or subsequent line of therapy. See NCCN guidelines for more details in the case of resistance to Afatinib in the presence of mutant EGFR. 		National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.	Guideline
Rearrangement	*-ALK			Lung Cancer		ALK Inhibitors	Drug Class	1			ALK rearrangement, notably with EML4, may suggest sensitivity to Crizotinib as a first or subsequent line of therapy. See NCCN guidelines for more details in the case of resistance to Crizotinib in the presence of ALK rearrangement. 		National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.	Guideline
Mutation	IDH1	SNV		Glioma		Alkylating Chemotherapy	Drug Class	1	1		Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).		National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	Guideline
Mutation	IDH2	SNV		Glioma		Alkylating Chemotherapy	Drug Class	1	1		Mutation of IDH2 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).		National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	Guideline
CNV	AR	Amplification		Prostate Cancer	Castration Resistant Prostate Cancer	Androgen Deprivation Therapy	Drug Class	0			Androgen receptor activation is a potential mechanism of recurrence of prostate cancer during androgen deprivation therapy.		National Comprehensive Cancer Network. Prostate Cancer NCCN Evidence Blocks (Version 3.2016). https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf. Accessed November 5, 2016.	Guideline
Mutation	TET2			Myelodysplastic Syndromes		AzaC	Drug Class	1		FDA-Approved	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	Guideline
Mutation	EGFR	SNV		Lung Cancer		AZD3759	ed Drug	1		Level A	Cabozantinib (a dual MET-VEGF inhibitor) is being evaluated for efficacy in patients with RET fusion-positive tumors.	10.1158/2159-8290.CD-13-0035	Drilon A, Wang L, Hasanovic A, et al. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov. 2013;3(6):630-5.	Journal
Mutation	EGFR	SNV		Lung Cancer		Cabozantinib+Erlotinib	Targeted Drug	1		Level A	Cabozantinib (a dual MET-VEGF inhibitor) in combination with erlotinib is being evaluated in patents with EGFR mutations.	10.1016/j.tips.2016.09.003	Ke EE, Wu YL. EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?. Trends Pharmacol Sci. 2016;37(11):887-903.	Journal
Mutation	EGFR	SNV		Lung Cancer		Capmatinib+Gefitinib	Targeted Drug	1		Level A	Capmatinib (a cMET inhibitor) is being evaluated in combination with gefitinib in patients with EGFR mutations.	10.1016/j.tips.2016.09.003	Ke EE, Wu YL. EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?. Trends Pharmacol Sci. 2016;37(11):887-903.	Journal
Mutation	KRAS	SNV		Colorectal Cancer	Metastatic	Cetuximab	Targeted Drug	0		FDA-Approved	KRAS alterations predict resistance to treatment with cetuximab, both alone and in combination with alkylating chemotherapy; cetuximab may have a detrimental effect on these patients.		National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	Guideline
Mutation	NRAS	SNV		Colorectal Cancer	Metastatic	Cetuximab	Targeted Drug	0		FDA-Approved	NRAS alterations predict resistance to treatment with Cetuximab, both alone and in combination with alkylating chemotherapy.		National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	Guideline
Rearrangement	EML4-ALK	Fusion		Lung Cancer	Metastatic	Crizotinib	Targeted Drug	1		FDA-Approved	ALK rearrangement, notably with EML4, may suggest sensitivity to Crizotinib as a first or subsequent line of therapy. See NCCN guidelines for more details in the case of resistance to Crizotinib in the presence of ALK rearrangement. 		National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.	Guideline
Rearrangement	BCR-ABL1	Fusion		Chronic Myeloid Leukemia	Chronic Phase CML	Dasatinib	Targeted Drug	1		FDA-Approved	Translocations predict sensitivity to tyrosine kinase inhibitors such as imatinib, dasatinib, and nilotinib. Secondary mutations can cause resistance to these agents. Nilotinib or Bosutinib are second-line and subsequent therapies for cytogenetic or hematologic resistance to TKIs		National Comprehensive Cancer Network. Chronic Myelogenous Leukemia (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf. Accessed November 5, 2016.	Guideline
Mutation	EGFR	SNV		Lung Cancer	Metastatic	Erlotinib	Targeted Drug	1		FDA-Approved	Mutant EGFR may suggest sensitivity to Erlotinib as a first or subsequent line of therapy. See NCCN guidelines for more details in the case of resistance to Erlotinib in the presence of mutant EGFR.		National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.	Guideline
Mutation	EGFR	SNV		Lung Cancer	Metastatic	Gefitinib	Targeted Drug	1		FDA-Approved	Mutant EGFR may suggest sensitivity to Gefitinib as a first or subsequent line of therapy. See NCCN guidelines for more details in the case of resistance to Gefitinib in the presence of mutant EGFR. 		National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.	Guideline
CNV	EGFR	Amplification		Lung Cancer		Gefitinib	Targeted Drug	1		Level A	Amplification and mutation of EGFR was associated with better clinical outcomes in a trial of 66 non-small cell lung cancer patients who had experienced relapse after surgery.	10.1200/JCO.2005.01.0793	Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005;23(28):6829-37.	Journal
Mutation	EGFR	Amplification		Lung Cancer		Gefitinib	Targeted Drug	1		Level A	Amplification and mutation of EGFR was associated with better clinical outcomes in a trial of 66 non-small cell lung cancer patients who had experienced relapse after surgery.	10.1200/JCO.2005.01.0793	Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005;23(28):6829-37.	Journal
Mutation	TET2			Myelodysplastic Syndromes		Hypomethylating agents	Drug Class	1		FDA-Approved	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	Guideline
Mutation	EGFR	SNV		Lung Cancer		Icotinib	Targeted Drug	1		Level A	Mutant EGFR may suggest sensitivity to Icotinib as a first or subsequent line of therapy.	10.1016/j.tips.2016.09.003	Ke EE, Wu YL. EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?. Trends Pharmacol Sci. 2016;37(11):887-903.	Journal
Rearrangement	BCR-ABL1	Fusion		Chronic Myeloid Leukemia	Chronic Phase CML	Imatinib	Targeted Drug	1		FDA-Approved	Translocations predict sensitivity to tyrosine kinase inhibitors such as imatinib, dasatinib, and nilotinib. Secondary mutations can cause resistance to these agents. Dasatinib, Nilotinib, or Bosutinib are second-line and subsequent therapies for cytogenetic or hematologic resistance to TKIs		National Comprehensive Cancer Network. Chronic Myelogenous Leukemia (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf. Accessed November 5, 2016.	Guideline
Mutation	TP53	Nonsense|Frameshift|Splice Site		Myelodysplastic Syndromes		Lenalidomide	Targeted Drug	0	0	Level B	More frequent with complex karyotypes and del(5q).		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	Guideline
Mutation	TP53	Missense		Myelodysplastic Syndromes		Lenalidomide	Targeted Drug	0	0	Level B	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	Guideline
CNV	PTEN	Deletion		Pancreatic Cancer		mTOR Inhibitors	Drug Class	1		Level D	PTEN loss in the setting of KRAS G12D mutation was associated with an increased sensitivity to mTOR inhibition in a mouse model.	10.1136/gutjnl-2013-306202	Morran DC, Wu J, Jamieson NB, et al. Targeting mTOR dependency in pancreatic cancer. Gut. 2014;63(9):1481-9.	Journal
CNV	MIR17HG	Amplification		Rectal Cancer		Neoadjuvant Chemotherapy+Surgery	Procedure	1		Level D	Amplification of the 13q31-34 region, which contains MIR17HG, was associated with increased sensitivity to neoadjuvant chemotherapy and surgery in 41% of participants in a 120-patient study.	10.2147/OTT.S105760	Molinari C, Salvi S, Foca F, et al. miR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer. Onco Targets Ther. 2016;9:2735-42.	Journal
CNV	MIR17HG	Deletion		Rectal Cancer		Neoadjuvant Chemotherapy+Surgery	Procedure	0		Level D	Deletion of the 13q31-34 region, which contains MIR17HG, was associated with resistance to neoadjuvant chemotherapy and surgery in 41% of participants in a 120-patient study.	10.2147/OTT.S105760	Molinari C, Salvi S, Foca F, et al. miR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer. Onco Targets Ther. 2016;9:2735-42.	Journal
Rearrangement	BCR-ABL1	Fusion		Chronic Myeloid Leukemia	Chronic Phase CML	Nilotinib	Targeted Drug	1		FDA-Approved	Translocations predict sensitivity to tyrosine kinase inhibitors such as imatinib, dasatinib, and nilotinib. Secondary mutations can cause resistance to these agents. Dasatinib or Bosutinib are second-line and subsequent therapies for cytogenetic or hematologic resistance to TKIs		National Comprehensive Cancer Network. Chronic Myelogenous Leukemia (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf. Accessed November 5, 2016.	Guideline
CNV	MDM2	Amplification		Gastic Cancer	Metastatic	nutlin-3	Targeted Drug	1		Level D	Presence of amplified MDM2 may suggest sensitivity to nutlin-3 in the absense of mutant TP53.		Endo S, Yamato K, Hirai S, et al. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells. Cancer Sci. 2011;102(3):605-13.	Journal
Mutation	TP53	SNV		Gastic Cancer	Metastatic	nutlin-3	Targeted Drug	0		Level D	Presence of mutant TP53 may suggest resistance to nutlin-3.		Endo S, Yamato K, Hirai S, et al. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells. Cancer Sci. 2011;102(3):605-13.	Journal
Mutation	EGFR	SNV		Lung Cancer		Osimertinib	Targeted Drug	1		FDA-Approved	Osimertinib is FDA-Approved for metastatic non-small cell lung cancer patients with EGFR T790M mutations.	10.1186/s13045-016-0268-z	Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9:34.	Journal
Mutation	KRAS	SNV		Colorectal Cancer	Metastatic	Panitumumab	Targeted Drug	0		FDA-Approved	KRAS alterations predict resistance to treatment with cetuximab, both alone and in combination with alkylating chemotherapy; cetuximab may have a detrimental effect on these patients.		National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	Guideline
Mutation	NRAS	SNV		Colorectal Cancer	Metastatic	Panitumumab	Targeted Drug	0		FDA-Approved	NRAS alterations predict resistance to treatment with Panitumumab, both alone and in combination with alkylating chemotherapy.chemotherapy.		National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	Guideline
Germline Mutation	BRCA1	SNV		Ovarian Cancer		PARP Inhibitors	Drug Class	1		FDA-Approved	Patients with chemotherapy-refractory ovarian cancer have higher response rates to PARP inhibitor therapy in the presence of BRCA1 and BRCA2 mutations, particularly concomittant with platinum-sensitive disease. Platinum-resistant disease partially abrogates olaparib sensitvity in the setting of BRCA1 and BRCA2 mutations.		National Comprehensive Cancer Network. Ovarian Cancer NCCN Evidence Blocks (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/ovarian_blocks.pdf. Accessed November 5, 2016.	Guideline
Germline Mutation	BRCA2	SNV		Ovarian Cancer		PARP Inhibitors	Drug Class	1		FDA-Approved	Patients with chemotherapy-refractory ovarian cancer have higher response rates to PARP inhibitor therapy in the presence of BRCA1 and BRCA2 mutations, particularly concomittant with platinum-sensitive disease. Platinum-resistant disease partially abrogates olaparib sensitvity in the setting of BRCA1 and BRCA2 mutations.		National Comprehensive Cancer Network. Ovarian Cancer NCCN Evidence Blocks (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/ovarian_blocks.pdf. Accessed November 5, 2016.	Guideline
Mutation	BRCA1	SNV		Pancreatic Cancer		PARP Inhibitors	Drug Class	1		Level A	The presence of alterations in BRCA mutated pancreatic tumors is associated with increased sensitivity to PARP inhibitors.	10.2147/OTT.S30793	Benafif S, Hall M. An update on PARP inhibitors for the treatment of cancer. Onco Targets Ther. 2015;8:519-28.	Journal
Mutation	BRCA2	SNV		Pancreatic Cancer		PARP Inhibitors	Drug Class	1		Level A	The presence of alterations in BRCA mutated pancreatic tumors is associated with increased sensitivity to PARP inhibitors.	10.2147/OTT.S30793	Benafif S, Hall M. An update on PARP inhibitors for the treatment of cancer. Onco Targets Ther. 2015;8:519-28.	Journal
Germline Mutation	BRCA1	SNV		Ovarian Cancer		Pazopanib	Targeted Drug	1		Level A	Pazopanib may increase PFS in patients whose disease does not progress following first-line treatment.		National Comprehensive Cancer Network. Ovarian Cancer NCCN Evidence Blocks (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/ovarian_blocks.pdf. Accessed November 5, 2016.	Guideline
Germline Mutation	BRCA2	SNV		Ovarian Cancer		Pazopanib	Targeted Drug	1		Level A	Pazopanib may increase PFS in patients who Cancer		Platins	Drug Class	1		Level A	When present alongside genomic instability, the inactivation of DNA maintenance genes (BRCA1, BRCA2, or PALB2) was associated with increased sensitivity to platinum therapy in pancreatic cancer patients.	10.1038/nature14169	Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495-501.	Journal
Mutation	BRCA2	SNV		Pancreatic Cancer		Platins	Drug Class	1		Level A	When present alongside genomic instability, the inactivation of DNA maintenance genes (BRCA1, BRCA2, or PALB2) was associated with increased sensitivity to platinum therapy in pancreatic cancer patients.	10.1038/nature14169	Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495-501.	Journal
Mutation	PALB2	SNV		Pancreatic Cancer		Platins	Drug Class	1		Level A	When present alongside genomic instability, the inactivation of DNA maintenance genes (BRCA1, BRCA2, or PALB2) was associated with increased sensitivity to platinum therapy in pancreatic cancer patients.	10.1038/nature14169	Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495-501.	Journal
Mutation	KRAS	SNV		Lung Cancer		Trametinib+FGFR1 Inhibitor	Targeted Drug	1		Level D	The combination of trametinib (a MEK inhibitor) with inhibition of FGFR1 is shown to enhance lung cancer and pancreatic cancer tumor cell death in vitro and in vivo.	doi:10.1038/nature18600	Manchado E, Weissmueller S, Morris JP, et al. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature. 2016;534(7609):647-651.	Journal
Mutation	KRAS	SNV		Pancreatic Cancer		Trametinib+FGFR1 Inhibitor	Targeted Drug	1		Level D	The combination of trametinib (a MEK inhibitor) with inhibition of FGFR1 is shown to enhance lung cancer and pancreatic cancer tumor cell death in vitro and in vivo.	10.1038/nature18600	Manchado E, Weissmueller S, Morris JP, et al. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature. 2016;534(7609):647-651.	Journal
CNV	ERBB2	Amplification		Gastric Cancer	Metastatic	Trastuzumab+Chemotherapy	Targeted Drug	1		Level A	Patients with HER2 overexpression or amplification showed significant improvement in median overall survival with the addition of trastuzumab to chemotherapy compared to chemotherapy alone. This benefit is limited to patients with a tumor score of IHC 3 + or IHC 2 + and FISH positive.		National Comprehensive Cancer Network. Gastric Cancer NCCN Evidence Blocks (Version 3.2016). https://www.nccn.org/professionals/physician_gls/pdf/gastric_blocks.pdf. Accessed November 5, 2016.	Guideline
Mutation	EGFR	SNV		Lung Cancer		Tyrosine-Kinase Inhibitor	Drug Class	1			There is significant association between EGFR mutants and sensitivity to EGFR TKIs.		National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.	Guideline
Mutation	EGFR	InDel		Lung Cancer		Tyrosine-Kinase Inhibitor	Drug Class	0			EGFR exon 20 insertions may predict resistance to TKIs.		National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.	Guideline
Mutation	KRAS			Lung Cancer		Tyrosine-Kinase Inhibitor	Drug Class	0			KRAS mutations are associated with intrinsic resistance to EGFR TKIs.		National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.	Guideline
